The short answer
SEER reports a 98.2% five-year relative survival rate for prostate cancer overall. Localized and regional prostate cancer are both essentially 100.0%; distant (metastatic) disease is 40.1%. Grade group and PSA trends matter as much as stage for most men's treatment decisions.
A survival statistic describes a large group diagnosed years ago — not a prediction for any one person.
For prostate cancer, the five-year relative survival rate for everyone combined, diagnosed 2016–2022, was 98.2%.
Stage at diagnosis makes a large difference: localized disease is 100.0% versus 40.1% for distant (metastatic) disease.
Grade group (from the Gleason score) and PSA trends often matter more than SEER stage for treatment decisions.
Choose how you want to understand this
The full explanation.
Before you look at the numbers
Three things are true about the numbers below. Read them before you read a single percentage.
First, a "5-year relative survival rate" for prostate cancer describes a large group of people. Those people were diagnosed with prostate cancer years ago. It is not a prediction about you. Everyone's prostate cancer, body, and treatment plan are different.
Second, this data lags behind today's care. These figures reflect people diagnosed with prostate cancer between 2016 and 2022. Newer hormone therapies for advanced prostate cancer have kept improving since then. So have other treatments. So prostate cancer treatment today may already work better than these numbers suggest.
Third, an all-stages number blends very different people together. It mixes people with early, easy-to-treat cancer with people whose cancer had already spread. For prostate cancer, the stage-specific numbers below beat one blended average. And "5-year" is just a measurement window researchers use for consistency. It is not a life expectancy for anyone with prostate cancer. It is not a deadline either.
The SEER numbers for prostate cancer
SEER's most recent report covers people diagnosed with prostate cancer between 2016 and 2022. Across every stage combined, the five-year relative survival rate was 98.2%. Most prostate cancer is found early, and it grows slowly. That is why the overall number is so high.
Localized and regional prostate cancer both round to 100.0% five-year relative survival. The difference from the overall average comes almost entirely from distant disease.
| Stage at diagnosis | 5-year relative survival |
|---|---|
| Localized — confined to the prostate | 100.0% |
| Regional — spread to nearby lymph nodes | 100.0% |
| Distant — spread to other parts of the body | 40.1% |
| Unknown/unstaged | 94.1% |
What "relative survival" actually means
Relative survival compares two groups. One is people with prostate cancer. The other is people in the general population who are the same age and sex but do not have cancer. Say the relative survival rate is 100%. That means people with the cancer were, as a group, about as likely to be alive at 5 years as people without it. It is not the same as the share of people who are cancer-free. And it is not the share of people who die from the cancer itself.
Most prostate cancer has a very high survival rate. So doctors often focus less on the SEER stage. They look instead at grade group, which is based on the Gleason score, and at PSA trends. Those help decide between active treatment and active surveillance. A high overall survival rate does not mean every case is low-risk.
What actually changes your outlook
A statistic describes a group. Your own outlook depends on things specific to you:
- Stage — how far the prostate cancer has spread, as shown in the table above.
- Grade — how abnormal the cancer cells look under a microscope, and how fast they tend to grow.
- Grade group (Gleason score) — describes how abnormal the cancer cells look and how likely they are to grow quickly.
- PSA level and trend — a blood marker that helps track the cancer over time.
- How your cancer responds to treatment — early scans and lab results often tell your care team more than the statistics at diagnosis do.
- Your overall health — other medical conditions, age, and general fitness all affect treatment options and recovery.
- Access to care — timely diagnosis, specialist care, and the ability to complete treatment all matter.
Questions for your care team
- Which SEER stage describes my prostate cancer, and what is its five-year number?
- Which biomarkers or molecular tests matter in prostate cancer, and were they run on my sample?
- How do my age and overall health change these prostate cancer statistics for me?
- Are there newer prostate cancer treatments available now that this data doesn't reflect yet?
- Beyond the general prostate cancer statistics, what does my team expect in my case?
- Where can I find support for how it feels to hear these prostate cancer numbers?
- What is my grade group, and how does it compare to my PSA trend in guiding treatment choice?
If these numbers are hard to sit with
You may feel scared, numb or overwhelmed after reading survival statistics. That is a normal reaction. It does not mean you are handling a prostate cancer diagnosis the wrong way. Many people find it easier to take these numbers in slowly, with someone else in the room. Others skip the numbers altogether until they are ready. Cancer Anxiety and Uncertainty covers the fear these prostate cancer numbers can stir up. It is also worth telling your prostate cancer team how much detail you want, and when.
Sources
Words to know
Tap any term to see what it means.
Common questions
What does 98.2% five-year relative survival mean for prostate cancer?
It means that, on average, people diagnosed with prostate cancer between 2016 and 2022 were about 98.2% as likely to be alive 5 years later as people of the same age and sex without prostate cancer. It blends every stage together, from early to advanced.
Why is the stage-specific number so different from the overall number?
The overall number blends people found early, when prostate cancer is most treatable, with people found later. Stage makes a large difference — see the table above. Localized prostate cancer usually has a much higher five-year relative survival than distant (metastatic) disease.
Does this number predict what will happen to me?
No. This is a statistic about a large group of people, not a prediction about you. Your age, overall health, tumor biology, and how your prostate cancer responds to treatment all shape your individual outlook in ways a group statistic cannot capture.
Is this the most current data available?
It is the most recent data SEER has published, but it still reflects people diagnosed in 2016–2022. Treatments keep changing, so people diagnosed today may do better than these numbers suggest.
If the numbers are this high, why do some men still need aggressive treatment?
A high overall survival rate reflects the fact that most prostate cancer is low-grade and slow-growing. But some prostate cancers are higher-grade and grow faster, and these need more active treatment. Your grade group and PSA trend, not just the general statistic, guide that decision.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Last updated: 2026-08-17Next planned review: 2027-08-03
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share